药学学报杂志

CN外文-月刊 知网 万方目次 维普目次 CSCD 科核 药学

1、投稿方式：在线投稿。

2、刊内网址：

http://www.yxxb.com.cn（网站升级，暂无法登陆）

http://www.elsevier.com/locate/apsb

自动跳转至：

https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b

3、投稿系统：

https://www.editorialmanager.com/apsb/

4、出刊日期：月刊，每月25日出版。

5、不收版面费审稿费。

2022年9月6日星期二

《药学学报（英文版）》投稿须知

【2022年06期信息】

Information for Authors

Acta

Pharmaceutica Sinica B is an English language bimonthly peer-reviewed

journal published online in ScienceDirect which invites research

articles, reviews and communications in all areas of the pharmaceutical

sciences. It is one of a series of Acta Pharmaceutica Sinica journals

founded in 1953 and sponsored by the Institute of Materia Medica,

Chinese Academy of Medical Sciences and the Chinese Pharmaceutical

Association. It is produced and hosted by Elsevier B. V.

1. Scope of submitted manuscripts

The

journal invites original articles and review papers dealing with all

aspects of the pharmaceutical sciences including pharmacology,

pharmaceutics, medicinal chemistry, natural products, pharmacognosy,

pharmaceutical analysis and pharmacokinetics.

Review

articles: These should encompass new and important aspects of study and

should describe research results and provide a critical analysis of the

issue.

Original articles: These should deal with new, significant and innovative findings based on recent research.

Communications:

Articles should contain new and important information that is likely to

be of interest to readers and makes urgent publication desirable.

2. Submissions of manuscripts

Manuscripts

should be submitted online via EVISE® at

http://www.evise.com/evise/faces/pages/navigation/NavController.jspx?JRNL_ACR=APSB

by registering and logging into this website. The system is easy to use

and allows authors to submit papers online and track their progress

through the editorial process.

Prior

or duplicate publications are not accepted. All manuscripts, especially

data, must not have been published or submitted for publication

elsewhere. The authors should make a full disclosure of any past

submissions. Submitted manuscripts should be accompanied by a covering

letter giving: (1) the title of the manuscript; (2) a statement that the

manuscript has not been published in part or whole (except in the form

of abstract) nor is under consideration for publication elsewhere in any

language.

The

source of financial assistance and other support must be acknowledged.

The contribution of colleagues or institutions should also be

acknowledged.

3. Peer-review

3.1 Manuscript receipt

Upon

receipt of a manuscript, the Editorial Office will immediately assign a

code number which should be used in all subsequent correspondence. An

acknowledgement of receipt letter will be sent to the corresponding

author. After pre-review by the editors, most submitted manuscripts will

be sent to expert reviewers for peer-review. All manuscripts are

subject to editorial modification.

3.2 Revision

On

receipt of comments from the Editorial Office, the authors should

revise their manuscript, answer the comments one by one and indicate the

page and line of each correction to the manuscript. A revised

manuscript will be considered a new submission if not returned to the

Editorial Office within 1 month. Revised versions labeled with the

manuscript code number should be sent electronically or by e-mail.

3.3 Rejected manuscripts

If a manuscript is not accepted for publication, the authors will receive a decision letter along with the reviewers’ comments.

3.4 Proof reading

Checking

the proofs is solely the authors’ responsibility. Answer any queries on

the proof itself. Corrections are restricted to printer’s errors and

should be made legibly (preferably by typing) in the margins. Use

universally accepted proofreader’s signs and symbols. If the authors

feel the need to include new information, it should be inserted as a

“Note added in proof” and will be included with the permission of the

Editorial Office.

3.5 Copyright Assignment Form

Papers

accepted for publication become the copyright of Acta Pharmaceutica

Sinica B and authors will be asked to sign a transfer of copyright form.

All authors must read and agree to the conditions outlined in the

Copyright Assignment Form and must sign it. Articles will not be

published until a signed Copyright Assignment Form has been received.

Authors

should return the proof and Copyright Assignment Form within 3 days to

the Editorial Office. If the time limit is exceeded, publication of the

article may be delayed.

4. Organization of the manuscript

4.1 Title

The

title of the manuscript must be informative, specific and brief (<30

words). Words should be chosen carefully to facilitate the retrieval

process. Minimal use of nonfunctional words is encouraged.

4.2 Authors and affiliation

Each

author should have participated sufficiently in the work to take public

responsibility for the content. Capitalize the first letter in the

surname(s) and spell out the given name(s) in full-name form, e.g.

Jiandong Jiang. Any change in authorship must be approved in writing by

all authors. The corresponding author should be indicated by an asterisk

(*) to the right of the corresponding author’s name and their telephone

number, fax number and e-mail address given in the footnote. The

affiliation of each author should also be given.

4.3 Abstract

The

abstract should describe the aim, general methods, results and

conclusions of the manuscript. It should be presented as a single

paragraph following the title page.

4.4 Key words

Authors

should provide 5–8 key words or phrases drawn from those recommended by

the US National Library of Medicine’s Medical Subject Headings (MeSH)

browser list at http://www.nlm.nih.gov/mesh/meshhome.html. If a suitable

MeSH term is not available, a more general term suitable for indexing

may be used.

4.5 Text

4.5.1

Introduction: This should provide a concise summary of the topic based

on relevant references and should give a clear description of the

purpose of the study being reported or reviewed.

4.5.2

Materials and methods: This should provide sources of the main drugs,

chemicals and instruments (including manufacturers and specifications)

used in the study and should provide sufficient technical information to

allow the experiments to be repeated. New methods or modifications to

existing methods should be described in detail.

Drug

nomenclature: International Nonproprietary Names (INN) or generic names

should be employed whenever possible. The first letter of the drug name

should be lowercase for INN or generic names, but capitalized for

proprietary names.

Species

nomenclature: The scientific names [genus, species (in italic form) and

authority] of all plants, animals and microorganisms should be given.

Common names may be used in certain circumstances. For crude drug names,

put name of medicinal parts first (in standard form).

Experimental

subjects: The authors should indicate the grade of animals used in

experiments. Rats and mice should be at least specific pathogen free.

The sex, age and body weight of tested animals (or humans in clinical

studies) should be given as mean, standard deviation and total range.

Animal experiments should adhere to instructions for the care and use of

animals provided by the appropriate Ethics Committee. Human experiments

may be performed only in accordance with the ethical standards and

permission of the responsible committee of the institution at which the

work was carried out.

4.5.3

Quantities, units, and numerical values: SI units must be used for

example: length (m, cm, mm, μm, nm), mass (kg, g, mg, μg), volume (L,

mL, μL), time (s, min, h, d), temperature (°C, K), radiation (Bq, dpm),

concentration [mol/L, mmol/L, mg/mL, μg/mL, % (v/v), % (w/v)]. Physical

quantities should be printed in italic type e.g. t (h). When an Arabic

number precedes an SI unit, the unit symbol should be used rather than

the full name of the unit, for example, 1 min (one minute), 2 h (two

hours). No unit is required for relative molecular mass.

4.5.4

Abbreviations: These must only be used after being spelled out in full

at their first appearance followed by the abbreviation in parentheses.

Routes of administration may be abbreviated e.g. intravenous (iv),

intramuscular (im), intraperitoneal (ip), subcutaneous (sc),

intracerebroventricular (icv), intraarterial (ia), per oral (po),

intragastric gavage (ig).

4.5.5

Numbers and effective digits: The effective digits in a datum are

determined by the variation within the sample which is one-third of the

standard deviation. For example: 4820.5 ± 340.8 g should be 4.8 ± 0.3

kg. For other expression of numbers, use 2%–6% (not 2–6%), 5×104–7×104

(not 5–7×104) and 2 mm × 3 mm × 4 mm (not 2×3×4 mm).

4.5.6

Tables and figures: Each table and figure should have a legend that is

self-explanatory (intelligible without reference to the text) and should

avoid repetition of data in the text. Tables are preferable to figures

especially if the figure is a simple histogram. Indicate the number (n)

and character of observations and subjects.

Tables

should be numbered consecutively with Arabic numerals followed

immediately by its legend. Each column in a table should have a short or

abbreviated heading with the unit in parentheses. If an experimental

condition is the same for all of the tabulated experiments (e.g. the n),

give this information in a statement accompanying the table.

Figures

must not include handwritten or typewritten lettering. The intervals

should be integers so that the interpolation will permit accurate

evaluation of the points. Symbols and curves can be identified in the

figure itself or in the legend. Broader lines should be drawn for curves

than for the axes. Avoid wasting space. Combine related curves in a

single figure when possible to save space and convey more information.

Do not extrapolate curves nor extend the axes far beyond the contents.

When feasible, curves should be transformed into straight lines with the

aid of logarithm, reciprocal, probit, logit, etc. Indicate scales by

short index lines and repeat the index lines on the opposite side unless

more than one scale is used. The resolution of each figure should be:

line art 1000 dpi, monochrome 600 dpi and colorful figure 300 dpi (or

higher).

Photographs

must be of the highest quality with good contrast. Color photographs

are welcome. With photomicrographs, only the essential parts should be

shown: a second small photomicrograph at higher magnification is usually

more informative than a single large one. Scale markers (e.g. 1 μm)

should be put inside the photomicrographs. Briefly explain the symbols,

arrows, numbers, or letters in the illustrations.

Identify

the method of staining and magnification of the photomicrographs (e.g.

HE stain, ×900). The resolution of each photograph should be 300 dpi (or

higher).

For

submission, TIFF, PSD, AI, JPEG and EPS are recommended acceptable

formats for the figures, which should be submitted separately. Maximum

width of tables and figures should be 80 mm (single column) and 160 mm

(double column). Please use only one typespace of writing in any one

diagram (Helvetica, Arial or Times New Roman).

4.5.7

Nomenclature: For chemical compounds, this should be in accordance with

the nomenclature rules formulated by IUPAC. Alternatively naming may

conform to that given in the index of Chemical Abstracts or the Ring

Index. Stereochemical information (cis, Z, R, etc.), locants (N-methyl,

α-amino) and symmetry designations (C2v) should also be italicized.

Chemical formula(e) should be numbered with boldface Arabic numerals

(e.g. 1). Abbreviations such as Me, Et, n-Bu, i-Pr, s-Bu, t-Bu, and Ph

may be used. General substituents should be indicated by R1, R2 etc or

R, R′

etc. The spatial arrangement of substituents should be indicated by

hatched lines or a wedge.A minus sign must be as long as the crossbar of

a plus sign.

4.5.8

Confirmation of structure: Adequate evidence to establish structural

identity must accompany all new compounds that appear in the

Experimental Section of Original Articles and Communications. Generally,

the physical and chemical parameters of new compounds should be given

in the following order: m.p. (b.p.); [α]D; UV-vis λmax; IRυ, 1H NMR and

13C NMR; MS m/z; elemental analyses or HRMS data. List only IR

wavelengths that are diagnostic for key functional groups.

4.5.9

Statistical methods: These should be described when they are used to

verify the results. Suitable techniques should be chosen for statistical

treatments e.g. t-test (group or paired comparisons), chi-square test,

Ridit, probit, regression (linear, curvilinear, or stepwise),

correlation, analysis of variance (ANOVA), analysis of covariance, etc.

Only homogeneous data can be averaged. Standard deviations are preferred

to standard errors. Give the number of observations and subjects (n).

Identify

statistical significance by superscripts in front of the probabilities

(P): *P<0.05, **P<0.01, ***P<0.001 vs A; △P<0.05, △△P<0.01, △△△P<0.001 vs B.

Values

such as ED50, LD50, IC50 should have their 95% confidence limits

calculated and compared by weighted probit analysis (Bliss and Finney).

The word “significantly” should be replaced by its synonyms (if it

indicates extent) or the P value (if it indicates statistical

significance).

4.5.10

Results and discussion: These should emphasize or summarize only

important observations. Give absolute values rather than percentages

particularly for control values. Present your results followed by tables

or figures and reserve extensive interpretation of the results for the

discussion section. In the discussion, emphasize new and important

findings and relate your results to other studies. Discuss the

shortcomings or limitations of your experiments. New hypotheses and

recommendations may be proposed when warranted.

4.5.11

Acknowledgments: These may briefly include acknowledgement of

assistance from: (i) contributors that do not warrant authorship; (ii)

technical help; and (iii) material support.

4.6 References

Please

ensure that every reference cited in the text is also present in the

reference list (and vice versa). Superscript numbers should be given

before punctuation. Any references cited in the manuscript must be given

in complete form. Unpublished results and personal communications

should be avoided in the reference list but may be mentioned in the

text. If such references are included in the reference list, they should

follow the standard reference style of the journal and should include a

substitution of the publication date with either "Unpublished results"

or "Personal communication". Citation of a reference as "in press"

implies that the item has been accepted for publication.

Reference

style: The titles of journals should be abbreviated according to the

“List of Journals Indexed” in Index Medicus (www.nlm.nih.gov). List all

authors, but if the number exceeds 6 give the names of 6 authors

followed by et al.

Text:

Indicate references by superscript numbers in the text. The actual

authors can be referred to in the text but the reference number(s) must

always be given.

List: Number the references in the list in the order in which they appear in the text.

Examples:

Reference to a journal publication:

1. van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. J Sci Commun 2000;163:51–9.

Reference to a book:

2. Strunk Jr W, White EB. The elements of style. 3rd ed. New York: Macmillan; 1979.

Reference to a chapter in an edited book:

3. Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith RZ, editors.

Introduction to the electronic age. New York: E-Publishing Inc; 1999. p. 281–304.

Reference to a patent:

4.

Larsen CE, Trip R, Johnson CR, inventors; Novoste Corporation,

assignee. Methods for procedures related to the electrophysiology of the

heart. US patent 5,529,067. 1995 Jun 25.

For

further details you are referred to "Uniform Requirements for

Manuscripts submitted to Biomedical Journals" (J Am Med Assoc

1997;277:927–934)

Editoral Office of Acta Pharmaceutica Sinica

1 Xiannongtan Street, Beijing 100050

Tel: 86-10-63035116, 86-10-63026192;

Fax: 86-10-63026192;

E-mail: yxxb@imm.ac.cn

http://www.yxxb.com.cn, http://www.elsevier.com/locate/apsb

上一篇： 科技通报

下一篇：电气工程学报（原：电气制造）